Reality Check on Ovarian Cancer
Market access for ovarian cancer treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the medical benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In October 2019, the FDA expanded the label for Zejula (niraparib) to include the treatment of women with advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with at least three chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status
- Key Findings: Most products are limited by their policies for treatment at specific stages of ovarian cancer. This may not remain true as we see clinical trials proving that targeted therapies can provide improvement earlier in the disease cycle and during the maintenance phase
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.